ArticleBMC microbiology2026
Potential host-gut microbiota-metabolite associations in cardiorenal syndrome progression: a multi-omics integrative analysis.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe coexistence of heart failure (HF) and renal insufficiency, termed cardiorenal syndrome (CRS), significantly increases mortality in HF patients. Although gut microbiota-host metabolic interactions contribute to the pathology of both conditions, their regulatory mechanisms in CRS remain unclear.
methodsThis cross-sectional study enrolled 451 subjects from two medical institutions across different regions of China, comprising 155 patients with CRS, 225 with HF alone, and 71 controls. Using integrated metabolomics and 16S rRNA sequencing, we compared 801 serum metabolites, 36,956 microbial amplicon sequence variants, and 14 clinical parameters across the three groups. Additionally, associations between serum metabolites, gut microbiota, and clinical parameters in the HF and CRS groups were analyzed.
resultsCRS patients had significantly higher serum uric acid, creatinine, and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, along with lower hemoglobin and albumin levels, compared with HF patients (P < 0.05). Serum metabolomics identified 100 upregulated metabolites in CRS vs. HF (q-value < 0.1), including endogenous metabolites (3-hydroxybutanoic acid, L-homocitrulline) and gut-derived uremic toxins (3-methyloxindole, p-cresol). Additionally, the CRS group showed significantly reduced gut microbiota α-diversity compared with HF and controls, along with a trend toward reduction in several taxa with key metabolic functions, including Lachnospiraceae, Faecalibacterium, and Faecalibacterium_prausnitzii. Moreover, these microbial abundances negatively correlated with endogenous or gut-derived metabolites, while metabolite levels positively correlated with cardiorenal function markers (NT-proBNP, creatinine).
conclusionThis multi-omics study reveals a host-gut microbiota-metabolite association network in CRS, linking aberrant metabolites to microbiota dysbiosis and organ-toxic metabolite accumulation. These findings provide novel insights into CRS pathogenesis and potential targeted therapies.
trial registrationClinical trial number: ChiCTR2300071422.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.